We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed at $0.80 in the latest trading session, marking a -1.27% move from the prior day. This move lagged the S&P 500's daily gain of 7.03%. Meanwhile, the Dow gained 7.73%, and the Nasdaq, a tech-heavy index, added 7.33%.
Heading into today, shares of the company had lost 38.2% over the past month, lagging the Medical sector's loss of 8.85% and the S&P 500's loss of 16.9% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. In that report, analysts expect ACB to post earnings of -$0.04 per share. This would mark year-over-year growth of 50%. Our most recent consensus estimate is calling for quarterly revenue of $49.96 million, up 1.96% from the year-ago period.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.94 per share and revenue of $209.72 million. These results would represent year-over-year changes of -327.27% and +5.88%, respectively.
It is also important to note the recent changes to analyst estimates for ACB. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.22% higher within the past month. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed at $0.80 in the latest trading session, marking a -1.27% move from the prior day. This move lagged the S&P 500's daily gain of 7.03%. Meanwhile, the Dow gained 7.73%, and the Nasdaq, a tech-heavy index, added 7.33%.
Heading into today, shares of the company had lost 38.2% over the past month, lagging the Medical sector's loss of 8.85% and the S&P 500's loss of 16.9% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. In that report, analysts expect ACB to post earnings of -$0.04 per share. This would mark year-over-year growth of 50%. Our most recent consensus estimate is calling for quarterly revenue of $49.96 million, up 1.96% from the year-ago period.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.94 per share and revenue of $209.72 million. These results would represent year-over-year changes of -327.27% and +5.88%, respectively.
It is also important to note the recent changes to analyst estimates for ACB. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.22% higher within the past month. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.